Friday, 20 November 2026NewsWorldBusinessTech
Latest

Study Finds Nano Nitazoxanide Kills Oral Cancer Cells Better

Nano-formulated nitazoxanide reduced the viability of human oral squamous cell carcinoma cells more effectively than the standard tablet form in laboratory tests, researchers reported.

Nano-Formulation Outperforms Tablet

The study compared tablet-derived nitazoxanide (NTZ) with a nanostructured suspension (NTZ-NS) against SCC-9 cells, using non-malignant HaCaT keratinocytes as controls and cisplatin as a reference chemotherapy drug. The nano-formulation achieved an IC₅₀ of 2.628 µM versus 5.934 µM for the free drug.

SCC-9 cells treated with NTZ-NS showed late apoptosis at 35.6 ± 0.3% and sub-G1 accumulation at 19.00 ± 0.30%, compared with 28.3 ± 0.3% and 15.00 ± 0.30% for the tablet form. Both formulations altered S- and G2/M-phase distributions and lowered BCL2 and VEGF levels, with stronger effects observed for the nano-formulation. HaCaT keratinocytes maintained higher viability than cancer cells across tested concentrations, indicating a broader in-vitro selectivity margin rather than a complete absence of toxicity.

The experiments were conducted with n = 3 and statistical significance set at P < 0.05. The authors said therapeutic applicability cannot be inferred from the cell-culture data alone and support further preclinical evaluation.

Review Maps Esophageal Nanotechnology

Separately, a review published in Neoplasia examined nanotechnology platforms — including liposomes, albumin-bound nanoparticles, and polymeric nanoparticles — for esophageal squamous cell carcinoma, a distinct malignancy. That review graded evidence from clinical to conceptual and highlighted the gap between preclinical promise and clinical utility, as well as heterogeneity in the enhanced permeability and retention effect.

The review, titled “The landscape of nanotechnology in esophageal squamous cell carcinoma treatment,” appeared in Neoplasia on Nov. 10, 2026, as volume 83, article 101397, with doi 10.1016/j.neo.2026.101397. Authors Rui Wang and Xu Han at the fourth affiliated hospital of china medical university in Shenyang, 110032, Liaoning, China, synthesized ESCC-specific and supporting evidence on nanotechnology in ESCC treatment.

Omics Review Finds Validation Gaps

Another systematic review evaluated omics-informed resistance reversal in oral squamous cell carcinoma. It included 13 reports, with the highest therapeutic evaluation in animal models for nine studies, and concluded that heterogeneous interventions and limited independent validation prevent conclusions about clinical efficacy.

The review concluded that omics-informed perturbations were associated with improved treatment responses in preclinical OSCC models, but heterogeneous interventions, uneven methodological safeguards, and limited independent validation prevent conclusions about clinical efficacy, and that treatment-specific causal experiments and validation in authentic patient-derived systems are needed.

Study Builds Transcriptomic Risk Score

A study developed a transcriptomic risk score from a longitudinal cohort of 86 participants with oral leukoplakia, identifying epithelial proliferation and SPP1-related microenvironmental programs associated with transformation timing.

ACSS2 and ACLY Drive Metabolic Adaptation

Translating these insights into a therapeutic strategy, the researchers identified S8588 (VY-3-249), a quinoxaline-based small molecule originally reported as a selective ACSS2 inhibitor, as a potent dual-target agent.

S8588 simultaneously binds ACSS2 and ACLY, inducing their ubiquitination and proteasomal degradation, effectively dismantling the metabolic adaptability of OSCC cells and leading to profound suppression of lipogenesis and tumor growth. Isothermal Titration Calorimetry (ITC) using pCold-Trigger Factor (TF)-ACSS2/ACLY fusion proteins directly evaluated the binding affinity of S8588 to ACSS2 and ACLY.

Representative IHC staining and quantification of ACLY and ACSS2 in human oral tumour (n = 149) and adjacent tissues (n = 50) were performed. Kaplan–Meier survival analysis of 5-year overall survival was stratified by ACSS2 expression (low n = 52, high n = 97), ACLY expression (low n = 86, high n = 63), and combined ACLY/ACSS2 status (n = 38/48/14/49).

In vivo experiments showed S8588 treatment significantly suppressed tumor growth, with no significant impact on overall body weight, indicating a favorable safety profile.